{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:34:23Z","timestamp":1786368863761,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"DOI":"10.1186\/s12911-026-03537-7","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:34:20Z","timestamp":1780493660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of rule-based detection methods for relapse in multiple sclerosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Almaha","family":"Alfakhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud","family":"Almadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Alrwisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Albalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Alshihayb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Albogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shymaa","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad","family":"Alkhalifah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Al Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"Althunian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"3537_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0907839.","journal-title":"N Engl J Med"},{"key":"3537_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","volume":"72","author":"J Cohen","year":"2015","unstructured":"Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Obery\u00e9 J, et al. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. JAMA Neurol. 2015;72:1433. https:\/\/doi.org\/10.1001\/jamaneurol.2015.2154.","journal-title":"JAMA Neurol"},{"key":"3537_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376:221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"key":"3537_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. N Engl J Med. 2012;367:1087\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1206328.","journal-title":"N Engl J Med"},{"key":"3537_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med. 2011;365:1293\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa1014656.","journal-title":"N Engl J Med"},{"key":"3537_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med. 2006;354:899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med"},{"key":"3537_CR7","unstructured":"Wang C, Ruiz A, Mao-Draayer Y. Assessment and treatment strategies for a multiple sclerosis relapse. J Immunol Clin Res. 2018;5."},{"key":"3537_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7224\/1537-2073-14.3.148","volume":"14","author":"AP Ross","year":"2012","unstructured":"Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. Int J MS Care. 2012;14:148\u201359. https:\/\/doi.org\/10.7224\/1537-2073-14.3.148.","journal-title":"Int J MS Care"},{"key":"3537_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.msard.2017.11.022","volume":"19","author":"JJ Marriott","year":"2018","unstructured":"Marriott JJ, Chen H, Fransoo R, Marrie RA. Validation of an algorithm to detect severe MS relapses in administrative health databases. Mult Scler Relat Disord. 2018;19:134\u20139. https:\/\/doi.org\/10.1016\/j.msard.2017.11.022.","journal-title":"Mult Scler Relat Disord"},{"key":"3537_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13:618\u201325. https:\/\/doi.org\/10.3111\/13696998.2010.523670.","journal-title":"J Med Econ"},{"key":"3537_CR11","doi-asserted-by":"publisher","first-page":"103333","DOI":"10.1016\/j.msard.2021.103333","volume":"57","author":"L Liang","year":"2022","unstructured":"Liang L, Kim N, Hou J, Cai T, Dahal K, Lin C, et al. Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Mult Scler Relat Disord. 2022;57:103333. https:\/\/doi.org\/10.1016\/j.msard.2021.103333.","journal-title":"Mult Scler Relat Disord"},{"key":"3537_CR12","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1177\/1352458514528760","volume":"20","author":"P Flachenecker","year":"2014","unstructured":"Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, et al. Multiple sclerosis registries in Europe \u2013 results of a systematic survey. Multiple Scler J. 2014;20:1523\u201332. https:\/\/doi.org\/10.1177\/1352458514528760.","journal-title":"Multiple Scler J"},{"key":"3537_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1352458519892555","volume":"26","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult Scler. 2020;26:23\u201337. https:\/\/doi.org\/10.1177\/1352458519892555.","journal-title":"Mult Scler"},{"key":"3537_CR14","doi-asserted-by":"publisher","first-page":"e0231846","DOI":"10.1371\/journal.pone.0231846","volume":"15","author":"C Ohlmeier","year":"2020","unstructured":"Ohlmeier C, Gothe H, Haas J, Osowski U, Weinhold C, Blauwitz S, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS ONE. 2020;15:e0231846\u20130231846. https:\/\/doi.org\/10.1371\/journal.pone.0231846.","journal-title":"PLoS ONE"},{"key":"3537_CR15","doi-asserted-by":"publisher","first-page":"e0173353","DOI":"10.1371\/journal.pone.0173353","volume":"12","author":"J Alsop","year":"2017","unstructured":"Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T. Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLoS ONE. 2017;12:e0173353\u20130173353. https:\/\/doi.org\/10.1371\/journal.pone.0173353.","journal-title":"PLoS ONE"},{"key":"3537_CR16","doi-asserted-by":"publisher","first-page":"e0176174","DOI":"10.1371\/journal.pone.0176174","volume":"12","author":"G Izquierdo","year":"2017","unstructured":"Izquierdo G, Damas F, Paramo MD, Ruiz-Pena JL, Navarro G. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS ONE. 2017;12:e0176174\u20130176174. https:\/\/doi.org\/10.1371\/journal.pone.0176174.","journal-title":"PLoS ONE"},{"issue":"1 Pt 2","key":"3537_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jfma.2020.07.002","volume":"120","author":"CC Yang","year":"2021","unstructured":"Yang CC, Ro LS, Tsai NW, Lin CC, Huang WN, Tsai CP, et al. Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan. J Formos Med Assoc. 2021;120(1 Pt 2):542\u201350. https:\/\/doi.org\/10.1016\/j.jfma.2020.07.002.","journal-title":"J Formos Med Assoc"},{"key":"3537_CR18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-020-04726-6","volume":"42","author":"S Batista","year":"2021","unstructured":"Batista S, Nunes CC, Cerqueira JJ, Martins Silva A, Correia de Sa J, Ferreira J, et al. REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal. Neurol Sci. 2021;42:1995\u20132003. https:\/\/doi.org\/10.1007\/s10072-020-04726-6.","journal-title":"Neurol Sci"},{"key":"3537_CR19","doi-asserted-by":"publisher","first-page":"e88472","DOI":"10.1371\/journal.pone.0088472","volume":"9","author":"N Bergvall","year":"2014","unstructured":"Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS ONE. 2014;9:e88472\u201388472. https:\/\/doi.org\/10.1371\/journal.pone.0088472.","journal-title":"PLoS ONE"},{"key":"3537_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0035-2","author":"J Nicholas","year":"2018","unstructured":"Nicholas J, Boster A, Wu N, Yeh WS, Fay M, Kendter J, et al. Pharmacoecon open. 2018;2:31\u201341. https:\/\/doi.org\/10.1007\/s41669-017-0035-2. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data."},{"key":"3537_CR21","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1016\/j.jval.2019.09.1845","volume":"22","author":"P Bosco-Levy","year":"2019","unstructured":"Bosco-Levy P, Blin P, Lignot-Maleyran S, Lassalle R, Abouelfath A, Diez P, et al. Pnd75 Validation of an Algorithm Identifying Relapses in Multiple Sclerosis Using the French Nationwide Claims Database. Value Health. 2019;22:S750\u20131. https:\/\/doi.org\/10.1016\/j.jval.2019.09.1845.","journal-title":"Value Health"},{"key":"3537_CR22","doi-asserted-by":"publisher","first-page":"103928","DOI":"10.1016\/j.msard.2022.103928","volume":"63","author":"SG Ezabadi","year":"2022","unstructured":"Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S. Global assessment of characteristics of multiple sclerosis registries; A systematic review. Mult Scler Relat Disord. 2022;63:103928. https:\/\/doi.org\/10.1016\/j.msard.2022.103928.","journal-title":"Mult Scler Relat Disord"},{"key":"3537_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/ard-2022-222626","volume":"82","author":"R Knevel","year":"2023","unstructured":"Knevel R, Liao KP. From real-world electronic health record data to real-world results using artificial intelligence. Ann Rheum Dis. 2023;82:306\u201311. https:\/\/doi.org\/10.1136\/ard-2022-222626.","journal-title":"Ann Rheum Dis"},{"key":"3537_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu Rev Public Health. 2016;37:61\u201381. https:\/\/doi.org\/10.1146\/annurev-publhealth-032315-021353.","journal-title":"Annu Rev Public Health"},{"key":"3537_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/pds.5025","volume":"29","author":"FA Alnofal","year":"2020","unstructured":"Alnofal FA, Alrwisan AA, Alshammari TM. Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making. Pharmacoepidemiol Drug Saf. 2020;29:1303\u20136. https:\/\/doi.org\/10.1002\/pds.5025.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3537_CR26","doi-asserted-by":"publisher","first-page":"e065468","DOI":"10.1136\/bmjopen-2022-065468","volume":"13","author":"TA Althunian","year":"2023","unstructured":"Althunian TA, Alrasheed MM, Alnofal FA, Tafish RT, Mira MA, Alroba RA, et al. Recording type 2 diabetes mellitus in a standardised central Saudi database: a retrospective validation study. BMJ Open. 2023;13:e065468. https:\/\/doi.org\/10.1136\/bmjopen-2022-065468.","journal-title":"BMJ Open"},{"key":"3537_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000479515","volume":"48","author":"P Colais","year":"2017","unstructured":"Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, et al. Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology. 2017;48:171\u20138. https:\/\/doi.org\/10.1159\/000479515.","journal-title":"Neuroepidemiology"},{"key":"3537_CR28","volume-title":"Endotext [Internet]","author":"NC Nicolaides","year":"2018","unstructured":"Nicolaides NC, Pavlaki AN, Maria Alexandra MA, et al. Glucocorticoid Therapy and Adrenal Suppression. In: Feingold KR, Ahmed SF, Anawalt B, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2018."},{"key":"3537_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12874-021-01285-y","volume":"21","author":"NH Thurin","year":"2021","unstructured":"Thurin NH, Bosco-Levy P, Blin P, Rouyer M, Jov\u00e9 J, Lamarque S, et al. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data. BMC Med Res Methodol. 2021;21:95. https:\/\/doi.org\/10.1186\/s12874-021-01285-y.","journal-title":"BMC Med Res Methodol"},{"key":"3537_CR30","volume-title":"Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care","author":"National Clinical Guideline Centre (UK)","year":"2014","unstructured":"National Clinical Guideline Centre (UK). Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care. London, UK: National Institute for Health and Care Excellence; 2014."},{"key":"3537_CR31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/ije\/dyaa090","volume":"49","author":"MP Fox","year":"2020","unstructured":"Fox MP, Lash TL, Bodnar LM. Common misconceptions about validation studies. Int J Epidemiol. 2020;49:1392\u20136. https:\/\/doi.org\/10.1093\/ije\/dyaa090.","journal-title":"Int J Epidemiol"},{"key":"3537_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","volume":"5","author":"R Trevethan","year":"2017","unstructured":"Trevethan R, Sensitivity, Specificity, Values P. Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017;5:307. https:\/\/doi.org\/10.3389\/fpubh.2017.00307.","journal-title":"Front Public Health"},{"key":"3537_CR33","doi-asserted-by":"publisher","unstructured":"Monaghan TF, Rahman SN, Agudelo CW, Wein AJ, Lazar JM, Everaert K, et al. Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value. Med (Kaunas). 2021;57. https:\/\/doi.org\/10.3390\/medicina57050503.","DOI":"10.3390\/medicina57050503"},{"key":"3537_CR34","unstructured":"Carcaillon-Bentata L, Abouelfath A, Lignot-Maleyran S, Lassalle R, Jov\u00e9 J, Brochet B et al. Validation and improvement of an algorithm identifying relapses in multiple sclerosis (MS) within the French nationwide claims database. In: ISPE Annual Meeting. Washington, DC, USA: International Society for Pharmacoepidemiology; 2025."},{"key":"3537_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(02)07948-5","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002;359:881\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(02)07948-5.","journal-title":"Lancet"},{"key":"3537_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3109\/08958378.2014.955932","volume":"26","author":"LD Maxim","year":"2014","unstructured":"Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. Inhal Toxicol. 2014;26:811\u201328. https:\/\/doi.org\/10.3109\/08958378.2014.955932.","journal-title":"Inhal Toxicol"},{"key":"3537_CR37","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1093\/brain\/awx185","volume":"140","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. 2017;140:2426\u201343. https:\/\/doi.org\/10.1093\/brain\/awx185.","journal-title":"Brain"},{"key":"3537_CR38","doi-asserted-by":"publisher","unstructured":"Salter A, Lancia S, Sharma M, Cutter GR, Fox RJ, Marrie RA. Infection, relapses, and pseudo-relapses in individuals with multiple sclerosis. Neurol Clin Pract. 2025;15. https:\/\/doi.org\/10.1212\/CPJ.0000000000200493.","DOI":"10.1212\/CPJ.0000000000200493"},{"key":"3537_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.7224\/1537-2073.2023-064","volume":"26","author":"D Paredes","year":"2024","unstructured":"Paredes D, Lackey E, Shah S. Reasons for Hospital Admission in Individuals With Multiple Sclerosis. Int J MS Care. 2024;26:302\u20137. https:\/\/doi.org\/10.7224\/1537-2073.2023-064.","journal-title":"Int J MS Care"},{"key":"3537_CR40","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.msard.2020.102396","volume":"45","author":"V Cabreira","year":"2020","unstructured":"Cabreira V, Abreu P, Maia C, Costa A, S\u00e1 MJ. Trends in hospital readmissions in Multiple Sclerosis patients between 2009 and 2015. Mult Scler Relat Disord. 2020;45:102396. https:\/\/doi.org\/10.1016\/j.msard.2020.102396.","journal-title":"Mult Scler Relat Disord"},{"key":"3537_CR41","doi-asserted-by":"publisher","first-page":"17supplement228","DOI":"10.1212\/wnl.0000000000202826","volume":"100","author":"I Chin","year":"2023","unstructured":"Chin I, Moss H, Sands K, Kocher M, Akkas O, Torres A. Identifying Multiple Sclerosis Relapses from Clinical Notes Using Combined Rule-based and Deep Learning Methodologies (P3-3.001). Neurology. 2023;100:17supplement22829. https:\/\/doi.org\/10.1212\/wnl.0000000000202826.","journal-title":"Neurology"},{"key":"3537_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jiph.2018.02.005","volume":"11","author":"H Alharthi","year":"2018","unstructured":"Alharthi H. Healthcare predictive analytics: An overview with a focus on Saudi Arabia. J Infect Public Health. 2018;11:749\u201356. https:\/\/doi.org\/10.1016\/j.jiph.2018.02.005.","journal-title":"J Infect Public Health"},{"key":"3537_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366.","journal-title":"Ann Neurol"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-026-03537-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-026-03537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-026-03537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:04:02Z","timestamp":1786367042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12911-026-03537-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3537"],"URL":"https:\/\/doi.org\/10.1186\/s12911-026-03537-7","relation":{"references":[{"id-type":"doi","id":"10.1007\/s41669-017-0035-2","asserted-by":"subject"}]},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and has been approved by the institutional review board of Saudi Food and Drug Authority (SFDA) (Approval #2023_13) and King Abdullah International Medical Research Center (KAIMRC) (Approval #NRC23R\/589\/08); individual patient consent was waived by the approving ethics committees due to the retrospective design and use of de-identified data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All data used in this study were fully de-identified, and no information that could lead to the identification of individual participants is included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this paper are those of the author(s) and do not necessarily reflect those of the SFDA or its stakeholders. Guaranteeing the accuracy and the validity of the data is a sole responsibility of the research team.","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"302"}}